Survey on the treatment of non-small-cell lung cancer in Italy

A. Alexanian, V. Torri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The results of the Italian part of an international survey on therapeutic preferences and opinions about prognosis of patients affected by non-small-cell lung cancer (NSCLC) are shown. Patients and methods: The investigation was conducted by the means of a postal questionnaire aiming to gather information on preferences about treatment and beliefs about survival of three hypothetical patients affected by NSCLC in different stages (T2N1M0, T2N3M0, M1); three sources of Italian physicians potentially treating patients affected by NSCLC were the target population: participants in the Adjuvant Lung Project Italy (Alpi) trial, a 20% random sample of the Italian Medical Oncology Association (AIOM) and representatives of almost all the pneumology wards in Italy. Results: Overall, there were 287 evaluable responses, 89% of respondents were males, mean age was 46 years, years from graduation 21 and charge of patients per clinician 82. The most important result is the wide variation of answers both about therapy and prognosis. Expectations about size of prognosis improvement with a new chemotherapy seem to be excessive. Conclusions: The results are discussed in relation to the twin surveys of Canada and England and Wales and to the meta-analyses on the efficacy of chemotherapy as an adjunct to primary treatment and on postoperative radiotherapy in non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)807-813
Number of pages7
JournalAnnals of Oncology
Volume11
Issue number7
DOIs
Publication statusPublished - 2000

Fingerprint

Non-Small Cell Lung Carcinoma
Italy
Therapeutics
Drug Therapy
Pulmonary Medicine
Medical Oncology
Health Services Needs and Demand
Wales
England
Canada
Meta-Analysis
Radiotherapy
Surveys and Questionnaires
Physicians
Lung
Survival

Keywords

  • Adjuvant chemotherapy
  • Clinicians' opinions
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survey on the treatment of non-small-cell lung cancer in Italy. / Alexanian, A.; Torri, V.

In: Annals of Oncology, Vol. 11, No. 7, 2000, p. 807-813.

Research output: Contribution to journalArticle

@article{5e59a657bb844e6891a33ef2f988bd09,
title = "Survey on the treatment of non-small-cell lung cancer in Italy",
abstract = "Background: The results of the Italian part of an international survey on therapeutic preferences and opinions about prognosis of patients affected by non-small-cell lung cancer (NSCLC) are shown. Patients and methods: The investigation was conducted by the means of a postal questionnaire aiming to gather information on preferences about treatment and beliefs about survival of three hypothetical patients affected by NSCLC in different stages (T2N1M0, T2N3M0, M1); three sources of Italian physicians potentially treating patients affected by NSCLC were the target population: participants in the Adjuvant Lung Project Italy (Alpi) trial, a 20{\%} random sample of the Italian Medical Oncology Association (AIOM) and representatives of almost all the pneumology wards in Italy. Results: Overall, there were 287 evaluable responses, 89{\%} of respondents were males, mean age was 46 years, years from graduation 21 and charge of patients per clinician 82. The most important result is the wide variation of answers both about therapy and prognosis. Expectations about size of prognosis improvement with a new chemotherapy seem to be excessive. Conclusions: The results are discussed in relation to the twin surveys of Canada and England and Wales and to the meta-analyses on the efficacy of chemotherapy as an adjunct to primary treatment and on postoperative radiotherapy in non-small-cell lung cancer.",
keywords = "Adjuvant chemotherapy, Clinicians' opinions, Non-small-cell lung cancer",
author = "A. Alexanian and V. Torri",
year = "2000",
doi = "10.1023/A:1008313731133",
language = "English",
volume = "11",
pages = "807--813",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Survey on the treatment of non-small-cell lung cancer in Italy

AU - Alexanian, A.

AU - Torri, V.

PY - 2000

Y1 - 2000

N2 - Background: The results of the Italian part of an international survey on therapeutic preferences and opinions about prognosis of patients affected by non-small-cell lung cancer (NSCLC) are shown. Patients and methods: The investigation was conducted by the means of a postal questionnaire aiming to gather information on preferences about treatment and beliefs about survival of three hypothetical patients affected by NSCLC in different stages (T2N1M0, T2N3M0, M1); three sources of Italian physicians potentially treating patients affected by NSCLC were the target population: participants in the Adjuvant Lung Project Italy (Alpi) trial, a 20% random sample of the Italian Medical Oncology Association (AIOM) and representatives of almost all the pneumology wards in Italy. Results: Overall, there were 287 evaluable responses, 89% of respondents were males, mean age was 46 years, years from graduation 21 and charge of patients per clinician 82. The most important result is the wide variation of answers both about therapy and prognosis. Expectations about size of prognosis improvement with a new chemotherapy seem to be excessive. Conclusions: The results are discussed in relation to the twin surveys of Canada and England and Wales and to the meta-analyses on the efficacy of chemotherapy as an adjunct to primary treatment and on postoperative radiotherapy in non-small-cell lung cancer.

AB - Background: The results of the Italian part of an international survey on therapeutic preferences and opinions about prognosis of patients affected by non-small-cell lung cancer (NSCLC) are shown. Patients and methods: The investigation was conducted by the means of a postal questionnaire aiming to gather information on preferences about treatment and beliefs about survival of three hypothetical patients affected by NSCLC in different stages (T2N1M0, T2N3M0, M1); three sources of Italian physicians potentially treating patients affected by NSCLC were the target population: participants in the Adjuvant Lung Project Italy (Alpi) trial, a 20% random sample of the Italian Medical Oncology Association (AIOM) and representatives of almost all the pneumology wards in Italy. Results: Overall, there were 287 evaluable responses, 89% of respondents were males, mean age was 46 years, years from graduation 21 and charge of patients per clinician 82. The most important result is the wide variation of answers both about therapy and prognosis. Expectations about size of prognosis improvement with a new chemotherapy seem to be excessive. Conclusions: The results are discussed in relation to the twin surveys of Canada and England and Wales and to the meta-analyses on the efficacy of chemotherapy as an adjunct to primary treatment and on postoperative radiotherapy in non-small-cell lung cancer.

KW - Adjuvant chemotherapy

KW - Clinicians' opinions

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033821729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033821729&partnerID=8YFLogxK

U2 - 10.1023/A:1008313731133

DO - 10.1023/A:1008313731133

M3 - Article

C2 - 10997807

AN - SCOPUS:0033821729

VL - 11

SP - 807

EP - 813

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -